PJ 002
Alternative Names: PJ-002Latest Information Update: 27 Dec 2024
Price :
$50 *
At a glance
- Originator Chongqing Peg-Bio Biopharm
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Obesity; Type 2 diabetes mellitus
Most Recent Events
- 22 Oct 2024 Preregistration for Obesity (SC) (Chongqing Peg-Bio Biopharm, October 2024)
- 22 Oct 2024 Preregistration for Type 2 diabetes mellitus (SC) (Chongqing Peg-Bio Biopharm, October 2024)
- 21 Oct 2024 Phase-I clinical trials in Obesity (SC) prior to October 2024 (Chongqing Peg-Bio Biopharm, October 2024)